ATE179214T1 - Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen - Google Patents

Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen

Info

Publication number
ATE179214T1
ATE179214T1 AT93909997T AT93909997T ATE179214T1 AT E179214 T1 ATE179214 T1 AT E179214T1 AT 93909997 T AT93909997 T AT 93909997T AT 93909997 T AT93909997 T AT 93909997T AT E179214 T1 ATE179214 T1 AT E179214T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
antidiotypical
against lewis
antibodies against
specific
Prior art date
Application number
AT93909997T
Other languages
English (en)
Inventor
Helmut Eckert
Herbert Jaksche
Evelyne Janzek
Hans Loibner
Dieter Scholz
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929210944A external-priority patent/GB9210944D0/en
Priority claimed from GB929210930A external-priority patent/GB9210930D0/en
Priority claimed from GB929210929A external-priority patent/GB9210929D0/en
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE179214T1 publication Critical patent/ATE179214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Wood Science & Technology (AREA)
AT93909997T 1992-05-22 1993-05-14 Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen ATE179214T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929210944A GB9210944D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB929210930A GB9210930D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use
GB929210929A GB9210929D0 (en) 1992-05-22 1992-05-22 Monoclonal antibodies and their use

Publications (1)

Publication Number Publication Date
ATE179214T1 true ATE179214T1 (de) 1999-05-15

Family

ID=27266199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93909997T ATE179214T1 (de) 1992-05-22 1993-05-14 Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen

Country Status (20)

Country Link
EP (1) EP0644947B1 (de)
JP (3) JPH07507207A (de)
KR (1) KR100279317B1 (de)
AT (1) ATE179214T1 (de)
AU (1) AU678160B2 (de)
CA (1) CA2134751C (de)
CZ (1) CZ286547B6 (de)
DE (1) DE69324584T2 (de)
DK (1) DK0644947T3 (de)
ES (1) ES2133395T3 (de)
FI (1) FI111518B (de)
GR (1) GR3030701T3 (de)
HU (1) HU219055B (de)
NO (1) NO316120B1 (de)
NZ (1) NZ252161A (de)
PL (1) PL175651B1 (de)
RU (1) RU2208642C2 (de)
SG (1) SG50721A1 (de)
SK (1) SK281086B6 (de)
WO (1) WO1993024647A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500650B1 (de) 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
AU2004266216A1 (en) * 2003-08-14 2005-03-03 Ludwig Institute For Cancer Research Anti-Lewis Y anti-idiotypic antibodies and uses thereof
AT504231A1 (de) 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
US10150817B2 (en) 2010-09-01 2018-12-11 Biogen Ma Inc. Rapid generation of anti-idiotypic antibodies
RU2735653C2 (ru) * 2016-08-23 2020-11-05 Тран-Сцелл Биологицс Привате Лимитед Платформа с клетками-предшественниками человека для поиска активных веществ лекарственных препаратов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926454T2 (de) * 1988-07-06 1997-01-09 Verigen Inc N D Ges Des Staate Gegen hiv 1 gp48 spezifische antikörper
DE4006308A1 (de) * 1990-02-28 1991-08-29 Sandoz Ag Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom
DE4025499A1 (de) * 1990-08-11 1992-02-13 Sandoz Ag Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen
DK0528767T3 (da) * 1991-08-21 2000-04-17 Novartis Ag antistofderivater

Also Published As

Publication number Publication date
NO316120B1 (no) 2003-12-15
RU94046321A (ru) 1997-01-27
CZ286547B6 (cs) 2000-05-17
ES2133395T3 (es) 1999-09-16
DE69324584D1 (de) 1999-05-27
WO1993024647A1 (en) 1993-12-09
SG50721A1 (en) 2000-11-21
FI945485A (fi) 1994-11-22
CA2134751C (en) 2003-12-16
NO944443D0 (no) 1994-11-21
AU4068893A (en) 1993-12-30
JPH11178594A (ja) 1999-07-06
RU2208642C2 (ru) 2003-07-20
NZ252161A (en) 1996-10-28
JPH07507207A (ja) 1995-08-10
SK281086B6 (sk) 2000-11-07
KR950701685A (ko) 1995-04-28
EP0644947B1 (de) 1999-04-21
CA2134751A1 (en) 1993-12-09
SK139894A3 (en) 1995-07-11
EP0644947A1 (de) 1995-03-29
AU678160B2 (en) 1997-05-22
JP2006143738A (ja) 2006-06-08
NO944443L (no) 1995-01-20
FI111518B (fi) 2003-08-15
DE69324584T2 (de) 1999-09-23
HUT71311A (en) 1995-11-28
DK0644947T3 (da) 1999-11-01
HU219055B (hu) 2001-02-28
GR3030701T3 (en) 1999-11-30
KR100279317B1 (ko) 2001-01-15
PL175651B1 (pl) 1999-01-29
FI945485A0 (fi) 1994-11-22
CZ285194A3 (en) 1995-05-17

Similar Documents

Publication Publication Date Title
DE69230545D1 (de) Antikörperderivate
NZ568769A (en) Human monoclonal antibodies against CD20
DE69528823D1 (en) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
FI840219A0 (fi) Human-humanhybridom foer neoplasmer
ATE171207T1 (de) Monoklonaler antikörper
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
TW200500377A (en) Method of humanizing immune system molecules
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ATE179214T1 (de) Antiidiotypische monoklonale antikörper gegen den lewis y-spezifischen monoklonalen antikörper br55-2 und deren verwendungen
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
ATE115412T1 (de) Anti-idiotyp-antikörper gegen antimenschliche hochmolekulare, an melanomen assoziierte antigene.
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATE77243T1 (de) E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
DE69129582D1 (de) Antikörper gegen menschlichen plasmin-alpha 2-plasmininhibitor-komplex, hybridoma und immunoassay
MY115415A (en) Medicaments.
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
TW223019B (de)
BG50103A1 (en) Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 2 of malignant melanom in human
SE9404491D0 (sv) Process for the production of human monoclonal antibodies
PT94432A (pt) Processo para a producao sulfonamidas substituidas e compostos afins uteis no tratamento da asma, artrite e doencas afins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee